20/20 Biolabs, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2024-12-31 | 2024-09-30 | 2023-06-30 |
|---|---|---|---|---|
Revenue | $417 | $536 | $361 | $335 |
Gross Profit | 145 | 163 | 24 | 39 |
EBITDA | -780 | -1,217 | -1,856 | -1,727 |
EBIT | -800 | -1,249 | -1,890 | -1,767 |
Net Income | -825 | -1,249 | -1,873 | -1,716 |
Net Change In Cash | 417 | 536 | 361 | 335 |
Free Cash Flow | -536 | -1,411 | ||
Cash | 1,144 | 1,784 | 6,212 | |
Basic Shares | 4,856 | 4,804 | 4,804 | 4,769 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,752 | $1,424 | $11,059 | $9,622 |
Gross Profit | 360 | 109 | 5,121 | 4,694 |
EBITDA | -5,525 | -6,194 | 1,967 | 2,065 |
EBIT | -5,661 | -6,361 | 1,678 | 1,942 |
Net Income | -5,551 | -6,391 | 2,186 | 2,071 |
Net Change In Cash | 1,752 | 1,424 | 11,059 | 9,622 |
Free Cash Flow | -2,598 | -4,637 | 5,541 | -1,302 |
Cash | 1,784 | 4,089 | 8,807 | 3,354 |
Basic Shares | 4,800 | 4,768 | 9,487 | 9,463 |
